Vimarsana
Biggest News Aggregation in the World

Page 18 - Imaging Techniques News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Imaging Techniques. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Imaging Techniques Today - Breaking & Trending Today

New imaging technique can change the landscape of prostate cancer detection and treatment - Vimarsana News

New imaging technique can change the landscape of prostate cancer detection and treatment

Prostate-specific membrane antigen, or PSMA, -targeted PET imaging for prostate cancer has been a breakthrough diagnosis tool in locating prostate cancer tumors for more precise treatment.

New technique uses high-throughput sequencing to obtain ultra-high-resolution images of gene expression - Vimarsana News

New technique uses high-throughput sequencing to obtain ultra-high-resolution images of gene expression

The 30,000 or so genes making up the human genome contain the instructions vital to life. Yet each of our cells expresses only a subset of these genes in their daily functioning. The difference between a heart cell and a liver cell, for example, is determined by which genes are expressed--and the correct expression of genes can mean the difference between health and disease.

Global Cholestatic Jaundice Treatment market Trends and Vendors Analysis after Covid-19 Pandemic Opportunities Scenario Highlighting Major Drivers & Trends 2021-2028 – KSU - Vimarsana News

Global Cholestatic Jaundice Treatment market Trends and Vendors Analysis after Covid-19 Pandemic Opportunities Scenario Highlighting Major Drivers & Trends 2021-2028 – KSU

Global Cholestatic Jaundice Treatment market – Industry Trends and Forecast to 2028. A reliable report contains market data that can be relatively essential when it comes to dominate in the industry or make a mark in the market as a new emergent. It also strategically analyses the growth trends and future prospects. Moreover, this winning market report also provides strategic profiling of top players in the industry, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market. The report gives details about the top players and brands that are drivin...

New high-performance, safe MRI contrast agent for 3D vascular mapping - Vimarsana News

New high-performance, safe MRI contrast agent for 3D vascular mapping

New high-performance, safe MRI contrast agent for 3D vascular mapping Heart attack and stroke are the first and second leading causes of death in developed countries, respectively. As the disease often results in sudden death with few special prognostic symptoms, early diagnosis is very important. For this purpose, imaging techniques such as magnetic resonance imaging (MRI) are widely used to identify the narrowing or blockage of blood vessels. In MRI, contrast agents improve the visibility of the structures such as smaller blood vessels within the body. Just as satellites or global positioni...

Global $3.18 Bn Single-Cell Multi-Omics Markets, 2021-2025 - Increased Use of Single-Cell Technology Solutions for the Development of Therapeutics Drugs and Comprehensive Treatment Plan - Vimarsana News

Global $3.18 Bn Single-Cell Multi-Omics Markets, 2021-2025 - Increased Use of Single-Cell Technology Solutions for the Development of Therapeutics Drugs and Comprehensive Treatment Plan

Key Companies Profiled $3,188.9 Million Healthcare experts have found the single-cell multi-omics market to be one of the most rapidly evolving markets, which is predicted to grow at a CAGR of 21.16% during the forecast period, 2020-2025. The market is driven by the need for the development of an advanced solution based on single-cell technology for clinical research in various applications such as cancer, rare disease, cell biology, and synthetic biology, among others. The market is favored by the development of single-cell technology-based solutions for visualization and analysis of cell he...